Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12054509
Antimicrobial compounds, compositions, and uses thereof
granted -
US 12054501
Compositions and methods for inhibiting arginase activity
granted -
US 12053491
Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
granted -
US 12054537
Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
granted -
WO 2024162304
LIPIDE CARBAMOYLE OU LIPIDE D'URÉE AYANT CHACUN UNE AMINE CYCLIQUE, NANOPARTICULES LIPIDIQUES LE CONTENANT ET COMPOSITION PHARMACEUTIQUE
granted -
US 12059443
Method for treating cancer using dengue virus serotype 1 (DENV-1)
granted -
US 12059477
Nanomaterials
granted -
US 12060398
Fibrous proteinaceous networks and methods of use thereof
granted -
US 12060350
Therapeutic compounds and methods of use thereof
granted -
US 12059468
Carbohydrate conjugates as delivery agents for oligonucleotides
granted -
US 12059418
Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
granted -
US 12059407
Compositions and methods for delivery of macromolecules
granted -
US 12059214
System and method of performing treatment along a lumen network
granted -
US 12060558
Methods and compositions for treatment of cholesteryl ester storage disease
granted -
US 12060566
Self-inactivating lentiviral vector comprising a FOXP3 expression cassette
granted -
US 12061206
Diagnosis and treatment of autoimmune diseases
granted -
US 12060590
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12060555
MicroRNA-33 inhibitors and use thereof in the treatment of pulmonary fibrosis
granted -
US 12060382
Crystalline phases of 5,6-dichloro-2-(isopropylamino)-(1 β-L-ribofuranosyl)-1H-benzimidazole
granted -
US 12060362
Inhibitors of glucose transporters (GLUTs)
granted -
US 12060428
Anti-IL36R antibodies
granted -
US 12060419
CD79A chimeric antigen receptors
granted -
US 12060327
Psychotropic agents and uses thereof
granted -
US 12059471
Complex
granted -
US 12060346
Inhibitors of APOL1 and methods of using same
granted -
US 12059474
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
granted -
US 12059413
Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction
granted -
US 12059400
Medical compound
granted -
US 12059437
Methods and compositions for hematopoietic stem cell mobilization
granted -
US 12060396
Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis
granted -
US 12060497
Coatings containing polymer modified enzyme for stable self-cleaning of organic stains
granted -
UY 40647
DERIVADOS DE ETILSULFONA/SULFOXIMINA-PIRIDINA SUSTITUIDOS CON TETRAZOL
granted -
UY 40645
DERIVADOS DE ETIL-SULFOXIMA-PIRIDINA SUSTITUIDOS CON CICLOPROPIL-(HETERO)ARILO
granted -
UY 40646
DERIVADOS DE N-ÓXIDO DE ETIL-SULFONA/SULFOXIMINA-PIRIDINA SUSTITUIDOS CON CICLOPROPIL-(HETERO)ARILO
granted -
US 12064473
Cancer vaccines targeting Survivin and uses thereof
granted -
US 12065428
Anti-viral compounds
granted -
US 12065490
Chimeric antigen receptors and methods of making
granted -
US 12064399
Use of cannabinoids in the treatment of epilepsy
granted -
US 12065432
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
granted -
US 12066246
Target residual moisture content for lyophilized drug product
granted -
US 12065458
Trialkyne linking agents and methods of use
granted -
US 12064514
Ultrasound-sensitive peptide particles for spatially resolved molecule delivery
granted -
US 12064516
Pharmaceutical formulations and uses thereof
granted -
US 12064502
Peptide exhibiting wrinkle-improving activity and uses thereof
granted -
US 12064413
Methods of treating melanoma with S-equol
granted -
US 12064453
Biochemical and biomechanical conditioning for enhancing personalized mesenchymal stem cell therapies
granted -
US 12064433
Pyridone A2R antagonists
granted -
US 12064398
Parenteral formulations
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.